Business News

Have you learnt why Donald Trump was handled with remdesivir?

A study conducted by Gilead Sciences, maker of Remdesivir, found that the death rate of patients treated with the drug was 7.6% on day 14 of treatment.

Grow your business, Not your inbox

Stay up to date and subscribe to our daily newsletter now!

October
5, 2020

2 min read

This article was translated from our Spanish edition using AI technologies. Errors can occur due to this process.

Remdesivir blocks SARS-CoV-2 virus RNA polymerase, one of the key enzymes that the pathogen needs to replicate its genetic material (RNA) and multiply in the body of infected people.

US President Donald Trump started treatment with the drug remdesivir last Friday, said Sean Conley, a White House doctor.

Trump finished his first dose and will be on the drug for five days, added Dr. Brian Garibaldi added. The use of this drug was approved by the U.S. Food and Drug Administration on May 1 after research found positive effects from its use. Which?

A study by Gilead Sciences, the maker of Remdesivir, found that the death rate for patients treated with the drug was 7.6% on day 14 of treatment, compared with 12.5% ​​for patients who did not receive it. noted El Financial.

This analysis also showed that 74.4% of patients treated with Remdesivir recovered by day 14, compared with 59% of patients who received standard treatment only.

Depositphotos.com

Remdesivir blocks SARS-CoV-2 virus RNA polymerase, one of the key enzymes that the pathogen needs to replicate its genetic material (RNA) and multiply in the body of infected people.

The drug has already been tested in clinical trials in Mexico with positive results.

Related Articles